“Denmark-based Bavarian Nordic announced on Feb. 14, 2025 that its recombinant vaccine for chikungunya, marketed as Vimkunya, was approved by FDA for use in individuals aged 12 and older, the first such virus-like particle (VLP), single-dose vaccine for the chikungunya virus in the United States…

Chikungunya is a mosquito-borne disease caused by the virus of the same name (CHIKV) (1). Bavarian Nordic said CHIKV has been identified in more than 110 countries, and over the last five years, evidence of transmission has been confirmed in more than 50 countries. Also, CHIKV may be underreported or misdiagnosed as dengue fever due to a similar symptom profile.

Those symptoms, according to Bavarian Nordic, include fever, rash, fatigue, headache, and joint pain that can be severe or even incapacitating. Although most patients recover, as many as 40% may have chronic symptoms lasting anywhere from months to years (1).

More than 200 deaths from chikungunya were reported worldwide in 2024, out of 620,000 confirmed cases.”

From BioPharm.